Towards Healthcare
Hematologic Malignancies Treatment Market Expands USD 72.49 Billion in 2025

Hematologic Malignancies Treatment Market 2025 Overview Leukemia Leads, Lymphoma Grows Fastest, BTK Inhibitors Rise

Projections indicate that, the global hematologic malignancies treatment market increased from USD 67.32 billion in 2024 to USD 139.13 billion by 2034, experiencing a CAGR of 7.61% over the next 10 years.The global rise in the elderly population, who are more prone to blood cancers, is fueling the growth of the market.  

Content

  • Insight Code: 5963
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: August 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Kesiya Chacko is an accomplished market research professional with over 4+ years of experience in the healthcare industry, known for delivering actionable insights and strategic analysis that empower healthcare organizations to navigate complex, rapidly evolving markets.

Kesiya began her research career with Precedence Research, where she built a strong foundation in pharmaceutical and healthcare market analysis. Today, she plays an integral role at Towards Healthcare, contributing to in-depth, client-centric research initiatives. She also brings her expertise to Statifacts, supporting broader research functions with a focus on cross-sector healthcare trends and data interpretation.

Her commitment to high-quality analysis, combined with a strong grasp of regulatory and market dynamics, makes her a trusted contributor to healthcare firms seeking future-ready, data-backed decisions. Kesiya’s work spans the analysis of industry trends, competitive benchmarking, and evaluation of regulatory and innovation-driven shifts.

Talk to us
FAQ's

As of 2024, the global hematologic malignancies treatment market is valued at USD 67.32 billion. It is projected to reach USD 72.49 billion in 2025 and expand to USD 139.13 billion by 2034, growing at a CAGR of 7.61%.

Key growth drivers include rising global prevalence of blood cancers, increasing awareness and early diagnosis, advancements in targeted therapies and immunotherapies, supportive regulatory frameworks, growing clinical trials, and increased healthcare spending.

Common treatments include chemotherapy, radiation therapy, targeted therapy (e.g., tyrosine kinase inhibitors), immunotherapy (e.g., CAR-T cells, monoclonal antibodies), and stem cell transplantation. The choice of treatment depends on cancer type, stage, patient age, and overall health.

NIH, Leukemia & Lymphoma Society (LLS) (LLS), Blood Cancer Alliance, IABCD- Indian Association of Blood Cancer and Allied Diseases, US FDA, and GOV.UK, among others.
Any Questions